Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

10.94 -1.56 (-12.48%)
Streaming Delayed Price Updated: 1:48 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astri Therapeutics Inc

< Previous 1 2 Next >
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Preview For Astria Therapeutics
Via Benzinga
Expert Ratings for Astria Therapeutics
Via Benzinga
Astria Therapeutics: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know
Via Benzinga
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Outlook For Astria Therapeutics
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Dow Dips Over 800 Points; S&P 500 Down 2.8%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points. 
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end
Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for... 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Astria Therapeutics Gets FDA Nod For Initial-Stage Hereditary Angioedema Study
The U.S. Food and Drug Administration (FDA) announced clearance to Astria Therapeutics’ (NASDAQ: ATXS) Investigational New Drug (IND) application for STAR-0215 in the treatment of Hereditary Angioedema... 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.